Advanced or Recurrent Endometrial Carcinoma – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033 thelansis.com

Endometrial cancer is the most common gynecological cancer and typically carries a favorable prognosis, primarily due to the high percentage of patients diagnosed at early stages (75% at stage I and 13% at stage II). Relapse risk in endometrial cancer patients varies, ranging from 10–15% for early-stage disease to 40–70% for advanced stages, with most recurrences happening within the initial 3 years post-diagnosis. Median survival post-recurrence rarely surpasses 12 months, with time to relapse and a number of relapse sites independently affecting survival. Some patients may benefit from hormonal manipulation, systemic chemotherapies, or a combination of volume-directed radiotherapy and systemic chemotherapy, depending on residual disease post-surgery, recurrence site, prior therapies, and treatment intent (curative or palliative). Surgery, particularly salvage cytoreductive surgery, is primarily employed for central pelvic recurrences. Patients with advanced-stage disease or aggressive subtypes are at higher risk for both locoregional and distant recurrence.
• The prevalence of endometrial cancer in the United States is 25.7/100,000 women per year.

Thelansis’s “Advanced or Recurrent Endometrial Carcinoma Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033″ covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Advanced or Recurrent Endometrial Carcinoma treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Advanced or Recurrent Endometrial Carcinoma across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Advanced or Recurrent Endometrial Carcinoma Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Advanced or Recurrent Endometrial Carcinoma – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033